Download PDF
Exp Clin Endocrinol Diabetes 2015; 123(04): 260-264
DOI: 10.1055/s-0034-1394381
Article
© Georg Thieme Verlag KG Stuttgart · New York

Frequency of Dermatological Side Effects of Continuous Subcutaneous Insulin Infusion in Children and Adolescents with Type 1 Diabetes

E. Binder
1   Department of Pediatrics, Medical University of Innsbruck, Innsbruck
,
O. Lange
1   Department of Pediatrics, Medical University of Innsbruck, Innsbruck
,
M. Edlinger
2   Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Innsbruck
,
D. Meraner
1   Department of Pediatrics, Medical University of Innsbruck, Innsbruck
,
D. Abt
1   Department of Pediatrics, Medical University of Innsbruck, Innsbruck
,
C. Moser
1   Department of Pediatrics, Medical University of Innsbruck, Innsbruck
,
E. Steichen
1   Department of Pediatrics, Medical University of Innsbruck, Innsbruck
,
S. E. Hofer
1   Department of Pediatrics, Medical University of Innsbruck, Innsbruck
› Author Affiliations
Further Information

Publication History

received 11 June 2014
first decision 07 August 2014

accepted 01 October 2014

Publication Date:
21 January 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Background: The incidence of type 1 diabetes is rising, particularly in young infants. The treatment with continuous subcutaneous insulin infusion (CSII) offers certain benefits and has gained popularity. Insulin-pump therapy could be associated with cutaneous-adverse effects. The purpose of our study was to investigate the frequency and characterization of skin-related complications in patients with CSII.

Methods: In a single center setting, 54 patients (28 male, 26 female) on CSII therapy aged between 3 and 20 years participated in our study. Data including duration of diabetes, duration of CSII, pump model, catheter material, frequency of catheter switch and hygiene procedures at time of puncture were collected through a standardized questionnaire and photographs of affected areas of the skin were made. Statistical analysis was done to verify an association with gender, patients´ age, HbA1c values, and body mass index.

Results: Our observation revealed skin complications at the site of catheter insertion in 43% (8 f, 15 m) of our patients. A frequent occurrence of scars (24%, 6 f, 7 m), lipohypertrophic areas (20%, 4 f, 7 m) and eczema (11%, 1 f, 5 m) was observed. Furthermore, 6% (1 f, 2 m) showed changes in pigmentation and 6% (1 f, 2 m) lipoatrophy. The catheter localization had to be switched due to skin-complications in 24% (6 f, 7 m) whereas none of our patients discontinued insulin-pump therapy.

Conclusion: Skin-related complications during CSII are frequent and regular examination of the insertion sites is crucial. To verify the occurrence of lipoatrophy associated with insulin pump therapy – an otherwise rare complication – larger studies would be needed.

Keywords

type 1 diabetes - childhood diabetes - continuous subcutaneous insulin infusion - pump treatment - dermatological complications - lipoatrophy
 

  • References

  • 1 Patterson CC, Dahlquist GG, Gyürüs E et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-2010: a multicentre prospective registration study. Lancet 2009; 373: 2027-2033
    CrossrefPubMedGoogle Scholar
  • 2 Schober E, Waldhoer T, Rami B et al., Austrian Diabetes Incidence Study Group . Incidence and time trend of type 1 and type 2 diabetes in Austrian children 1999-2007. J Pediatr 2009; 155: 190-193
    CrossrefPubMedGoogle Scholar
  • 3 Schober E, Rami B, Waldhoer T. Austrian Diabetes Incidence Study Group . Steep increase of incidence of childhood diabetes since 1999 in Austria. Time trend analysis 1979-2005: A nationwide study. Eur J Pediatr 2008; 167: 293-297
    CrossrefPubMedGoogle Scholar
  • 4 Fox LA, Buckloh LM, Smith SD et al. A randomize control trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005; 28: 1277-1281
    CrossrefPubMedGoogle Scholar
  • 5 Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily injections in patients with diabetes mellitus: systemic review and meta-analysis. Diabetologia 2008; 51: 941-951
    CrossrefPubMedGoogle Scholar
  • 6 Churchill JN, Ruppe RL, Smaldone A. Use of continuous insulin infusion pumps in young children with type 1 diabetes: a systemic review. J Pedaitr Health Care 2009; 23: 173-179
    PubMedGoogle Scholar
  • 7 Jakisch BI, Wagner VM, Heidtmann B et al. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analyses over 3 years. Diabet Med 2008; 25: 80-85
    CrossrefPubMedGoogle Scholar
  • 8 Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003; 4: 661-667
    CrossrefPubMedGoogle Scholar
  • 9 Meyer L, Hadjadj S, Guerci B et al. Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion. Diabetes & Metabolism 1998; 23: 544-546
    PubMedGoogle Scholar
  • 10 Conwell LS, Pope E, Artiles AM et al. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr 2008; 152: 622-628
    CrossrefPubMedGoogle Scholar
  • 11 Schober E, Rami B. Dermatological side effects and complications of continuous subcutaneous insulin infusion in preschool-age and school-age children. PediatrDiab 2009; 10: 198-200
    PubMedGoogle Scholar
  • 12 Chantelau E, Lange G, Sonnenberg GE et al. Acute cutaneous complications and catheter needle colonization during insulin pump treatment. Diabetes Care 1987; 10: 478-482
    CrossrefPubMedGoogle Scholar
  • 13 Radermecker RP, Pierad GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J ClinDermatol 2007; 8: 21-28
    PubMedGoogle Scholar
  • 14 Mecklenburg RS, Benson EA, Benson JW et al. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA 1984; 252: 3265-3269
    CrossrefPubMedGoogle Scholar
  • 15 Legrand DA, Radermecker RP, Stassen MP et al. Staphylococcus aureus endocarditis in a diabetic woman treated by continuous subcutaneous insulin infusion. DiabetesMetab 2007; 33: 79-81
    PubMedGoogle Scholar
  • 16 Hahler B. An overview of dermatological conditions commonly associated with the obese patient. Ostomy Wound Manage 2006; 54: 34-36, 38, 40
    PubMedGoogle Scholar
  • 17 Chantelau E, Spraul M, Muhlhauser I et al. Long-term safety, efficacy and side-effects of continuous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 1989; 32: 421-426
    CrossrefPubMedGoogle Scholar
  • 18 Pickup JC, Yemane N, Brackenridge A et al. Nonmetabolic Complications of Continuous Subcutaneous Insulin Infusion: A Patient Survey. Diabetes Technology&Therapeutics 2014; 16: 1-5
    PubMedGoogle Scholar
  • 19 Hussein SF, Siddique H, Coates P et al. Lipoatrophy is a thing of the past, or is it?. Diabet Med 2007; 24: 1470-1472
    CrossrefPubMedGoogle Scholar
  • 20 Holstein A, Stege H, Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glarine and review of literature. Expert Opin Drug Saf. 2010; 9: 225-231
    CrossrefPubMedGoogle Scholar
  • 21 Chantelau E, Reuter M, Schotes S et al. A case of Lipoatrophy with Human Insulin-Therapy. ExpClinEndocrinol 1993; 101: 194-196
    PubMedGoogle Scholar
  • 22 Meyer L, Hadjadj S, Guerci B et al. Lipoatrophic diabetes mellitus treated by continous subcutaneous insulin infusion. Diabetes & Metabolism 1998; 23: 544-546
    PubMedGoogle Scholar
  • 23 Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause?. Diabetes Care 2001; 24: 174
    CrossrefPubMedGoogle Scholar
  • 24 Szypowska A, Skorka A, Pankowska E. Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus. Pediatr Endocrinol Diabetes Metab 2008; 14: 117-118
    PubMedGoogle Scholar
  • 25 Avery H. Insulin fat atrophy: a traumatic atrophic paniculitis. Br Med J 1929; i: 697
    PubMedGoogle Scholar
  • 26 Takatsuki H, Ishii H, Yamauchi T et al. A case of insulin allergy: the crystalline human insulin may mask its antigenicity. Diabetes Res Clin Pract 1991; May 12: 137-139
    CrossrefPubMedGoogle Scholar
  • 27 Reeves WG, Allen BR, Tattersall RB. Insulin-induced lipoatrophy. Evidence for an immune pathogenesis. Br Med J 1980; 280: 1500-1503
    CrossrefPubMedGoogle Scholar
  • 28 Chantelau EA, Praetor R, Praetor J et al. Relapsing insulin-induced lipoatrophy, cure by prolonged low-dose oral prednisone: a case report. Diabetology & Metabolic Syndrome 2011; 3: 33
    CrossrefPubMedGoogle Scholar
  • 29 Raile K, Noelle V, Landgraf R et al. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2001; 109: 393-396
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Atlan-Gepner C, Bongrand P, Farnarier C et al. Insulin-induced lipoatrophy in type 1 diabetes. A possible tumor necrosis factor-alpha mediated dedifferentiation of adipocytes. Diabetes Care 1996; 19: 1283-1285
    CrossrefPubMedGoogle Scholar
  • 31 Lopez X, Castells M, Ricker A et al. Human insulin analog-induced lipoatrophy. Diabetes Care 2008; 31: 442-444
    CrossrefPubMedGoogle Scholar